Damora Therapeutics(NASDAQ) DMRA

Damora Therapeutics develops new medicines for people with rare blood cancers. These treatments target the specific biological changes that cause bone marrow disorders. The company helps patients by trying to stop the body from overproducing blood cells.

Fighting Rare Blood Cancers

• DMR-001: Antibody designed to treat blood disorders like essential thrombocythemia; targets mutated proteins to reduce excess platelets.
• DMR-002: Second treatment candidate aiming for the same mutated proteins; uses an undisclosed method to address blood marrow diseases.
• DMR-003: Dual-action medicine that connects immune cells to cancer cells; planned for testing in 2027.
• Legacy Programs: Assets for lung and liver conditions; currently deprioritized as the company seeks partners for their development.

New Names and New Deals

• Acquired Pre-Acquisition Damora in November 2025 to gain access to a new pipeline of antibody treatments.
• Raised $285 million through a private investment with firms like Fairmount Funds Management and Viking Global Investors.
• Completed a public stock offering in February 2026 that provided roughly $297 million in net proceeds.
• Changed its name from Galecto to Damora Therapeutics in March 2026 to reflect its new business focus.

What Makes the Science Different?

Damora focuses on specific mutations found in blood marrow disorders, which allows treatments to ignore healthy cells. Their main drug candidate is designed for injection under the skin, making it more convenient than existing hospital-based infusions.

The Latest Financial Numbers

• Revenue was $0 in Q4 2025, which remained unchanged from the previous two years.
• Operating income dropped to -$201.7 million in Q4 2025, a figure that deepened from -$2.7 million in Q4 2024.
• Net income reached -$200.7 million in Q4 2025, worsening from a loss of -$6.7 million one year earlier.
• Free cash flow turned positive at $566,000 in Q4 2025, an improvement from -$11.5 million in Q4 2023.
• Operating cash flow reached $566,000 in Q4 2025, up 104.9% from two years prior.

Moving in a New Direction

Damora has transitioned from a general biotech firm to a specialist in targeted blood cancer treatments. By acquiring new technology and raising significant capital, it is rebuilding its business around a specific genetic target.